B+
Bull case
25%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
GHRS
GH ResearchDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive view is that GH001 now has peer-reviewed Phase 2b data, the FDA hold has been lifted, and cash was reported at $280.7 million at year-end 2025, giving GHRS a funded shot at moving into a global pivotal program if FDA alignment is achieved [#PR-2026-01-05] [#PR-2026-03-05] [#PR-2026-03-25].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.2.
What can break
FDA hold removal helps, but successful FDA alignment on the planned global Phase 3 design is still an unresolved execution gate.
Momentum
55
Value
41
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $36.00 · Bear $11.00Analysis 2026-04-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $41.70
Why
Momentum55 · Δ7d -13.3
Value41 · Δ7d 0.0
Sentiment44 · Δ7d +3.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.2.
Contradictions & invalidation
- • FDA hold removal helps, but successful FDA alignment on the planned global Phase 3 design is still an unresolved execution gate.
- • GHRS is pre-revenue, so valuation remains highly sensitive to development milestones rather than operating fundamentals.
- • The cautious view is that GHRS remains effectively a single-lead clinical story with limited forward visibility on exact Phase 3 timing, design agreement, device-bridging execution, and eventual regulatory/commercial acceptance; recent sector and policy headlines are not substitutes for company-specific de-risking.
Catalyst clock
2026-05-31
Peer-reviewed Phase 2b publication may support scientific credibility but is mostly a digestion catalyst
Lead driver: Sentiment · See AI snapshot
Momentum
55
9% active weight
Current posture
7d trendSoftening
Δ7d
-13.3
Δ21d
-36.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
44
62% active weight
Current posture
7d trendImproving
Δ7d
+3.2
Δ21d
+9.1
Why this grade
Composite grade D. Momentum 54.8 / Value 41.2 / Sentiment 43.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-28. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.06B
Beta
0.98
Shares Out
68.56M
P/E (TTM) · Derived
-37.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-36.15
Rev YoY
-
EPS YoY
+52.0%
Gross Margin
-
Op Margin
-
Net Debt
-$280.2M
Current Ratio
28.70
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data